Cheryl K. Mcdonald

Infectious Disease

1025 College Ave
Fort Worth, TX 76104

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Final efficacy and safety of twice-yearly subcutaneous lenacapavir in treatment-naive people with HIV.

Final efficacy and safety of twice-yearly subcutaneous lenacapavir in treatment-naive people with HIV.

Journal: AIDS (London, England)

Published: April 07, 2025

Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial.

Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial.

Journal: The lancet. HIV

Published: May 31, 2022

Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study.

Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study.

Journal: Journal of acquired immune deficiency syndromes (1999)

Published: November 16, 2020

Use of Drug-level Testing and Single-genome Sequencing to Unravel a Case of Human Immunodeficiency Virus Seroconversion on Pre-exposure Prophylaxis.

Use of Drug-level Testing and Single-genome Sequencing to Unravel a Case of Human Immunodeficiency Virus Seroconversion on Pre-exposure Prophylaxis.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: April 29, 2020

Clinical targeting of HIV capsid protein with a long-acting small molecule.

Clinical targeting of HIV capsid protein with a long-acting small molecule.

Journal: Nature

Published: November 26, 2019

Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve patients with HIV-1: subgroup analyses of the phase 3 AMBER study.

Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve patients with HIV-1: subgroup analyses of the phase 3 AMBER study.

Journal: HIV research & clinical practice

Published: July 16, 2019

Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3b trial.

Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3b trial.

Journal: The lancet. HIV

Published: May 25, 2018

Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results.

Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results.

Journal: Journal of acquired immune deficiency syndromes (1999)

Published: March 11, 2017

12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens.

12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: January 20, 2016

Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1.

Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1.

Journal: The New England journal of medicine

Published: July 22, 2015

Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study.

Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study.

Journal: Journal of acquired immune deficiency syndromes (1999)

Published: April 14, 2015

Cobicistat-boosted protease inhibitors in HIV-infected patients with mild to moderate renal impairment.

Cobicistat-boosted protease inhibitors in HIV-infected patients with mild to moderate renal impairment.

Journal: HIV clinical trials

Published: December 01, 2014

Showing 1-12 of 15

Last Updated: 09/26/2026